Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: Key drug screening and mechanism analysis

Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: Key drug screening and mechanism analysis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: Key drug screening and mechanism analysis Qian Tang, Xuefang Zheng, Yu Tang, Zhengping Xian, Fengjiao Wu, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4648678/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 29 Jul, 2024 Read the published version in Naunyn-Schmiedeberg's Archives of Pharmacology → Version 1 posted 10 You are reading this latest preprint version Abstract In the course of clinical treatment for anti-tumor, the combination of traditional Chinese medicine (TCM) and other treatment schemes can reduce toxicity and increase efficiency. The purpose of this paper is to find out the key TCM and effective components for the treatment of non-small cell lung cancer (NSCLC) and analyze its therapeutic mechanism by analyzing the prescription of TCM combined with chemotherapy for NSCLC. Firstly, the prescriptions of TCM in the randomized controlled trials combined with chemotherapy for NSCLC were collected, and the core TCM was screened by frequency statistics, association rule analysis and cluster analysis. Then, the intersection targets of the potential effects of NSCLC and core Chinese medicine were collected, and PPI analysis and enrichment analysis were performed on the intersection targets to screen the core targets, components and pathways, and the core components were verified by molecular docking and cell experiments. In this study, 269 prescriptions were collected, among which the frequency of medication for Astragalus membranaceus (HQ, in Chinese), Wolfiporia cocos (FL, in Chinese), Atractylodes macrocephala (BZ, in Chinese) was over 100. Association rule analysis showed that they were highly correlated and clustered into the same category in cluster analysis. Their core components were Quercetin, Kaempferol and Isorhamnetin. The molecular docking results of the core components with the core targets AKT1 and EGFR obtained by PPI network analysis showed that they could bind stably. KEGG analysis screened 110 pathways including PI3K-Akt; the results of CCK-8 showed that Quercetin, Kaempferol and Isorhamnetin could effectively inhibit the proliferation of A549 cells, and Isorhamnetin had the best inhibitory effect. Isorhamnetin can inhibit the migration and invasion of A549 cells, induce apoptosis, G1 phase arrest, and decrease the expression of P-PI3K and P-AKT in A549 cells. In a word, the key TCM for the treatment of NSCLC include HQ, FL, BZ, etc. and its key components Quercetin, Kaempferol, Isorhamnetin have potential therapeutic effects on NSCLC according to the research results. Non-small cell lung cancer Traditional Chinese medicine Medication rules Network pharmacology Molecular docking Experimental validation Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Introduction According to the report of the International Agency for Research on Cancer (IARC), the incidence (12.4 %) and mortality (18.7 %) of lung cancer in 2022 rank first (Bray et al. 2024), while the report of the National Cancer Center of China also shows that in 2022, China 's lung cancer will increase by 1.06 million and die by 730,000, which is also the cancer with the highest incidence and mortality (Zheng et al. 2022). Pathologically, lung cancer can be divided into small cell lung cancer and non-small cell lung cancer. NSCLC accounts for 80% - 85%, and 75% of patients are diagnosed at an advanced stage (St et al. 2020), which will make the patients miss the best treatment stage, so the 5-year survival rate of NSCLC patients is only 5.5% (Garon et al. 2019). At present, chemotherapy is one of the main treatment methods for NSCLC, but the survival rate of patients with advanced lung cancer receiving traditional chemotherapy is very low, and adverse reactions such as bone marrow suppression, liver and kidney function damage, and alopecia often occur, which seriously affects the quality of life of patients. Therefore, the methods of how to improve the therapeutic effect, patient survival rate and reduce adverse reactions are particularly important. As a traditional Chinese disease treatment plan, TCMs has the advantages of small side effects, non-invasiveness, low cost, and wide benefit population in tumor treatment. In recent years, many studies have shown that a variety of TCM components have anti-tumor activity (Chen et al. 2024; Yin et al. 2022; Yang et al. 2024), and the effect of reducing toxicity and increasing efficacy in the process of combined treatment with other treatment regimens is obvious. The multi-channel and multi-target treatment characteristics of TCMs can make up for the shortcomings of the current first-line treatment plans, such as single action pathway and large toxic and side effects. For example, Xiao et al. (Xiao et al. 2021) randomly divided 39 patients with stage III~IV NSCLC into TCM (Includes traditional Chinese medicine injection, traditional Chinese medicine decoction, capsule) combined with chemotherapy group and chemotherapy alone group. The results showed that the quality of life (QOL) score of the combined treatment group was higher, and the incidence of thrombocytopenia was significantly lower than that of the control group. There are also a number of studies that show that TCM has the effect of reducing toxicity and increasing efficiency (Wei et al. 2024; Zhang et al. 2022; Fei et al. 2023). Although modern pharmacological studies have shown that TCM can regulate TLR4/MyD88/NF-κB, P53, MAPK/TGF-β/Nrf2 and other signaling pathways (Zhao et al. 2024; Peng et al. 2020; Long et al. 2023), it can inhibit tumor proliferation, invasion and angiogenesis, so as to enhance drug sensitivity, reverse drug resistance, reduce adverse reactions and toxicity, and improve patient immunity (Zhang et al. 2024; Wang et al. 2020). However, due to the large number of components and targets of TCM, and the complex anti-tumor mechanism, and many components and mechanisms of action are not still clearly explained. Therefore, it is necessary to conduct in-depth research on it. In this study, the clinical randomized controlled literature of traditional Chinese medicine decoction combined with chemotherapy in the treatment of advanced NSCLC was excavated, and the prescriptions of traditional Chinese medicine were collected. The core TCM was screened out by frequency statistics, association rule analysis and cluster analysis. After that, the key targets and pathways of core TCM in the treatment of NSCLC were screened by network pharmacology analysis, and the key components were screened. In the end, they were verficated through molecular docking and cell experiment, to the results will provide reference for the treatment of NSCLC with TCM and the development of new drugs. Materials and methods Materials Quercetin, Kaempferol, CCK-8 kit were purchased from Aladdin (Shanghai, China); Isorhamnetin was purchased from Alfabiotech (Chengdu, China); Annexin V-FITC Apoptosis Detection Kit, Cell Cycle and Apoptosis Analysis Kit, Cell Plasma Membrane Staining Kit with DiO, Extracellular Matrix were purchased from Beyotime (Shanghai, China); PI, Recombinant Anti-GAPDH antibody, Prestained Protein Marker Ⅶ were purchased from Servicebio; Transwell chamber was purchased from NEST (Wuxi, China); Rabbit anti-PI3K, Rabbit anti-Phosphorylated PI3K, Goat Anti-Rabbit IgG were purchased from ZEN-BIOSCIENCE (Chengdu, China); Rabbit anti-AKT, Rabbit anti-Phosphorylated AKT were purchased from Proteintech (Wuhan, China); A549 cell line from ATCC (US). Methods Retrieval methodology 'Chinese traditional medicine ', ' non-small cell lung cancer ', ' NSCLC ', and ' chemical therapy ' were used as keywords to search CNKI, WanFang, VIP, Pubmed, Web of Science. The search date was from the establishment of the database to October 20, 2023. Literature inclusion and exclusion criteria Inclusion criteria: ①Type of study: RCT study; ②Subjects: patients with stage III~IV NSCLC diagnosed by histopathology and cytology; ③Intervention measures : the control group was only treated with conventional chemotherapy, and the experimental group was treated with traditional Chinese medicine decoction orally on the basis of the control group. Exclusion criteria: ①review, cell or animal test literature; ②subjects with other diseases, TNM stage I~II; ③Literatures on other western medicine treatment methods other than chemotherapy or other traditional Chinese medicine treatment methods other than oral Chinese medicine decoction were used in the experiment; ④The composition of the drugs in the prescription is unknown. Data extraction and collation The included prescriptions were sorted into the Excel table. If the literature contained multiple prescriptions, the multiple prescriptions would be included in the statistics separately. Due to the dialectical medication, the addition and subtraction on the basic side only recorded the basic side, and finally removed the repeated prescription. For the same TCM, if there are different drug names, it is unified as the only drug name; for the same TCM due to the use of different parts, origin, processing methods and have different effects are recorded respectively. Medication rule analysis The collected prescriptions of TCMs were used for frequency statistics to find out high-frequency drugs; then the association rule analysis and cluster analysis were carried out through the ' arules ' and ' fmsb ' packages of R language. The association rules were screened with support > 0.1 and confidence > 0.6, and the core drugs of TCM for NSCLC were screened according to the results. Targets collection The components of core drugs (OB > 30 %, DL > 0.18) were collected through TCMSP (https://tcmspw.com/tcms-p.php) database), and the components with antitumor activity confirmed by existing experiments but not included in TCMSP were supplemented by literature review. The potential targets of the collected components were collected through the SwissTargetPrediction (http:// www.swisstargetprediction.ch/) database (Probability > 0.15). NSCLC targets were collected from OMIM (https://www.omim.org/), GeneCards (https://www.genecards.org/), DisGeNET (https://www.disgenet.org/) and TTD (https://db.idrblab.net/ttd/) databases with the keyword ' non-small cell lung cancer '. The collected potential drug targets and NSCLC targets were deduplicated and intersected to obtain potential targets for drug treatment of NSCLC. PPI network construction The intersection targets were input into the STRING (https://cn.string-db.org/) database, and the species was set to ' Homo sapiens ', with the minimum action threshold > 0.4. The obtained PPI network was imported into Cytoscape 3.9.1, and the core targets were screened according to degree, betweenness centrality and closeness centrality, then the results were visualized. Enrichment analysis GO and KEGG analysis were performed through the ' Bioconductor ' package of R language to screen out the key pathways of key Chinese medicine in the treatment of NSCLC and visualize them. Molecular docking The protein structures of AKTI (PDB ID: 4ekl) and EGFR (PDB ID: 6lub) were obtained from PDB (https://www.rcsb.org/) database, and the active pockets of target proteins were predicted by DeepSite (https://playmolecule.com/) platform) (Jiménez et al. 2017). The protein was subjected to dehydration and hydrogenation by Pymol 2.6.0a0, and then molecular docking was performed by AutoDock 1.5.7. A549 cell culture The cells were cultured in F12K medium containing 10% fetal bovine serum at 37 °C, 5% CO 2 , and the medium was changed once a day. The cells were passaged when the degree of fusion reached 80%. Determined by cell viability assay The cell viability was detected by CCK-8 method. A549 cells were inoculated in 96-well plates at 5000 cells / well, with 5 replicate wells in each group. After the cells adhered to the wall, Quercetin, Kaempferol and Isorhamnetin were mixed with a concentration gradient of 0, 50, 100, 150, 200, 250 and 300 μmol/L for intervention, and the cell viability was detected at 24, 48 and 72 h, respectively. 100 μL CCK-8 working solution was added to each well for detection. After incubation for 30 min at 37 °C in dark, the OD value at 450 nm was detected by microplate reader, and the maximum and minimum values of each group were removed. Cell viability = (experimental OD-blank OD) / (control OD-blank OD) × 100%. Finally, the components with the best inhibitory effect were selected for subsequent experiments. Cell morphology observation A549 cells were inoculated on polylysine-treated slides and treated with 0 and 270 μmol / L for 48 h after cell attachment. Then, the cells were stained with Dio/PI staining solution (binding buffer: Dio: PI = 300: 1: 90), incubated for 20 min at 37 °C in the dark, the staining solution was removed, washed three times with PBS, and the cell morphology was observed under laser confocal microscopy. Cell migration The effect of isorhamnetin on the migration of A549 cells was verified by scratch test. A549 cells were inoculated in a 6-well plate to make the overnight fusion rate reach 100 %. The scratches were scratched with a 10 μL pipette tip, and then PBS was used to wash away the cell debris. The drug was prepared into 0, 90, 180, 270 μmol/L with F12 K medium containing 1% fetal bovine serum. After 48 h of treatment, the cell migration rate of each group was calculated. Cell migration rate = (0 h scratch area-48 h scratch area) / 0 h scratch area × 100 %. Cell invasion The effect of isorhamnetin on the invasion ability of A549 cells was verified by transwell assay. The matrigel was prepared according to the kit instructions and added to the upper chamber. After digestion, the cells were made into cell suspension with complete medium containing 0, 90, 180, 270 μmol/L drugs, respectively, inoculated in the upper chamber and cultured for 24 h at 37 °C. The cells and matrigel in the upper chamber were wiped off with a cotton swab, fixed with tissue fixative for 10 min, stained with 0.4% crystal violet, and photographed under an inverted microscope. Apoptosis and cell cycle The effects of isorhamnetin on apoptosis and cell cycle of A549 cells were detected by flow cytometry. Apoptosis: A549 cells were seeded in a 6-well plate and added to a complete medium containing 0, 90, 180, 270 μmol/L drugs after cell adherence. After culture of 48 h, cells were collected and stained with Annexin V-FITC and PI according to the kit instructions. After incubation of 20 min in the dark, the apoptosis was detected. Cell cycle arrest: Grouping and treatment methods are the same as apoptosis. Western blot The cells were treated with 0, 90, 180 and 270 μmol/L drugs, respectively. After 48 h, the total protein was extracted and quantified by BCA kit. The sample was loaded at 20 μg/well, and the protein was separated by SDS-PAGE electrophoresis at 200 V constant pressure and 400 mA constant flow membrane. BSA was blocked for 2 h, the primary antibody was incubated overnight at 4 °C, the secondary antibody was incubated at room temperature for 1 h, and the ECL developer was developed. The results were analyzed by Image J 1.54 f software. Results and analysis Literature retrieval results A total of 7714 articles were retrieved, including 2585 articles on CNKI, 3689 articles on Wanfang, 1142 articles on VIP, 60 articles on pubmed, and 238 articles on web of science. After removing the duplicate literature, the remaining 5310 articles were collected, 298 prescriptions were collected, finally, 269 prescriptions were remained after deleting the repeated prescriptions. Medication rule analysis A total of 295 traditional Chinese medicines were used from 269 prescriptions, and among them, the five most frequently used were HQ, FL, BZ, Ophiopogon japonicus (MD, in Chinese), Glycyrrhiza uralensis (GC, in Chinese) (Fig. 2A); the three drug pairs of BZ-HQ, Hedyotis diffusa(BHSSC, in Chinese)-HQ and BZ-FL were ranked the highest in support, and they were also the most frequently used in the analysis of association rules (Table1). After clustering analysis of TCMs, it was found that Codonopsis pilosula(DS, in Chinese), HQ, BZ and FL were clustered into the same category, which indicated that these TCMs have similar properties and functions (Fig. 2B). Due to the highest frequency and correlation of HQ, BZ and FL based on the above analysis results, they were selected as the core drugs for subsequent analysis. Table 1 Correlated herb pairs (top 10) couplet drugs support confidence degree BZ-HQ 0.29 0.74 79 BHSSC-HQ 0.29 0.81 78 BZ-FL 0.29 0.72 77 FL-HQ 0.29 0.66 77 MD-HQ 0.28 0.68 74 DS-HQ 0.27 0.71 72 GC-HQ 0.26 0.66 71 DS-BZ 0.25 0.65 66 DS-FL 0.23 0.62 63 CP-FL 0.18 0.72 47 * CP (Tangerine Peel, in Chinese) Network Pharmacology Analysis Core targets and component screening A total of 40 active ingredients of core drugs that met the screening conditions were collected from TCMSP, and 9 were supplemented through literature review (Xu et al. 2018; Chen et al. 2019; Zhang et al. 2019; Dou et al. 2021; Xu et al. 2021; Acharya et al. 2022; Mao et al. 2022; Zhang et al. 2022; Jiang et al. 2023). The collected components were imported into the SwissTargetPrediction database, then 156 potential targets that met the screening conditions were obtained. A total of 1309,1490,3926 and 168 NSCLC targets were collected from GeneCards, OMIM, DisGeNET and TTD databases, respectively. After removing duplicate targets, 5549 NSCLC targets were obtained. After intersecting the potential targets of active ingredients and NSCLC targets, 116 intersection targets were obtained, that is, the potential targets of core TCM in the treatment of NSCLC (Fig. 2C). According to the intersection targets obtained above, three key components were screened by sorting the degree values of the components corresponding to these targets: Quercetin, Kaempferol and Isorhamnetin. PPI network construction Table 2 Key targets of herbal medicine against NSCLC (top 10) Target Betweenness Closeness Degree AKT1 1955.66 0.01 65.00 EGFR 1547.19 0.01 60.00 ESR1 1281.93 0.01 52.00 PTGS2 1144.71 0.01 46.00 SRC 792.72 0.01 46.00 MMP9 356.01 0.01 41.00 GSK3B 393.78 0.01 37.00 PARP1 498.49 0.01 38.00 MCL1 257.82 0.01 32.00 KDR 214.27 0.01 32.00 The 116 intersection targets were imported into the STRING database to obtain the PPI network. The obtained PPI network was analyzed by Cytoscape and the screening condition was greater than the mean value, that is, degree > 14.85, closeness centrality > 0.0042, betweenness centrality > 129.01. The key targets of TCMs components in the treatment of NSCLC were screened (Table 2). Because the degree, betweenness centrality and closeness centrality of EGFR and AKT1 were significantly higher than those of other targets, they were identified as the core targets of Astragalus, Atractylodes and Poria in the treatment of NSCLC (Fig. 2D). Then, they were molecularly docked with the three core components (Quercetin, Kaempferol and Isorhamnetin) screened above. Enrichment analysis A total of 110 KEGG signaling pathways were enriched, including PI3K-Akt signaling pathway, EGFR tyrosine kinase inhibitor resistance, FoxO signaling pathway and other signaling pathways closely related to malignant tumors (Fig. 2E). 1982 GO entries was enriched by GO functional enrichment, involving 1703 biological processes, 90 cellular components, and 189 molecular functions (Fig. 2F). According to the results of KEGG enrichment, both the significance and the number of enriched intersection targets are higher in the PI3K-Akt signaling pathway, and existing studies have also shown that it is closely related to tumors (He et al. 2021; Khezri et al. 2022; et al. 2022). Therefore, we will futher verify it by Western blot experiments. In addition, we plotted the component-target-PI3K/Akt signaling pathway according to the corresponding relationship between PI3K-Akt pathway, targets and components (Fig. 2G). Molecular docking Table 3 Docking binding energy Components AKT1 kcal/mol EGFR kcal/mol Quercetin -6.53 -6.64 Isorhamnetin -6.58 -6.79 Kaempferol -6.25 -6.50 The results of molecular docking showed that the binding energies of the two core targets and the three key components were all less than -1.2 kcal/mol, which indicated that they could be spontaneously and stably combined, and that Quercetin, Kaempferol and Isorhamnetin could act on AKT1 and EGFR targets to play an anti-NSCLC role. Among them, the binding energy of EGFR and Isorhamnetin was the lowest (-6.79 kcal/mol) (Fig. 2H, Table 3). From the diagram, it could be found that the main forces between isorhamnetin and EGFR are Carbon Hydrogen Bond, Pi-Sigma, Pi-Sulfur and Pi-Alkyl. Isorhamnetin can form Pi-Alkyl bond with Lysa745, Alaa743 and Vala726 of EGFR, Pi-Sigma bond with Meta790, Leua718 and Leua844, Pi-Sulfur bond with Meta766, and Carbon Hydrogen Bond with meta793, Glna791, Glua792, Lysa745 and Leua718. Cell experiment Determined by cell viability assay In this experiment, the effects of Quercetin, Kaempferol and Isorhamnetin on the viability of A549 cells at 6 different concentrations and 3 time points were investigated. The results showed that the viability of A549 cells and the three components showed the dependence between dose and time. The difference between each treatment group and the blank group was statistically significant (P < 0.05), and the inhibitory effect of Isorhamnetin was the strongest. Therefore, the subsequent experiments focused on the effect of Isorhamnetin on A549 cells (Fig. 3A-D). The uncontrolled proliferation of cells is a major feature of tumors. When the tumor proliferates to a certain extent, it will transfer from the original lesion to other parts by means of tumor blood vessels. Therefore, the inhibition of tumor cell proliferation can effectively control tumor progression. It can be seen from the result that the viability of A549 cells was significantly inhibited after treatment with 100 μmol/L Isorhamnetin for 48 h. Cell morphology observation From the inverted microscope and confocal microscope, it could be found that the cell morphology of the blank group was full and irregular paving stone, while the cell morphology of the treatment group became elongated and slender. In the laser confocal microscope image, it could also be observed that the PI dye could not penetrate the membrane due to the integrity of the plasma membrane, , while the Dio dye could penetrate the membrane due to its lipophilicity in the normal group, so the cells in the normal group only have green fluorescence in the cytoplasmic region, while there is no red fluorescence in the nuclear region; however, for the treatment group, due to the influence of isorhamnetin, the cells began to apoptosis and the cell membrane was damaged. Therefore, most cells not only had green fluorescence in the cytoplasmic region, but also had red fluorescence in the nuclear region (Fig. 3E-H). The above results suggest that isorhamnetin will shrink the cytoplasm of A549 cells and recover the pseudopods, thus their morphology will change. At the same time, it will also promote the apoptosis of the cells and lead to the damage of the cell membrane. Cell migration The results of scratch test showed that the cell migration rates were 39.30%, 32.40%, 21.02% and 15.17% after 48 h treatment with Isorhamnetin at concentrations of 0, 90, 180 and 270 μmol / L, respectively. Although there was no significant difference between the 90 μmol/L group and the control group, the inhibition of cell migration ability became stronger with the increase of drug concentration. When 180 and 270 μmol/L were compared with the control group, the difference was statistically significant (P < 0.05), indicating that the higher the concentration of Isorhamnetin, the more significant the inhibition of A549 cell migration ability (Fig. 4A-H, M). NSCLC is easy to metastasize, which is closely related to poor prognosis. It can be seen from this experiment that although the low concentration group has no obvious inhibitory effect on the migration of A549 cells, with the increase of administration dose, the viability and migration ability of A549 cells are gradually inhibited. Its migration ability is concentration-dependent, indicating that isorhamnetin can effectively inhibit the migration of A549 cells. Cell invasion The results of this experiment showed that with the increase of dosage, the fewer cells penetrated the membrane. The number of A549 cells in the 0, 90, 180 and 270 μmol/L groups was (451 ± 23.52), (210 ± 17.52), (119.67 ± 4.93) and (71.67± 13.65), respectively. The difference between the administration group and the control group was statistically significant (P < 0.05) (Fig. 4I-L, N). Therefore, Isorhamnetin can effectively inhibit the invasion of A549 cells, and the higher the concentration, the stronger the inhibitory effect on its invasion ability. Apoptosis and cell cycle The effect of Isorhamnetin on the apoptosis of A549 cells was detected by FITC and PI staining. The results showed that the apoptosis rates of 0,90,180 and 270 μmol/L groups were 7.29%, 15.04%, 23.87% and 30.74 %, respectively. The early apoptosis rate of 90 μmol/L treatment group was 11.94%, while the late apoptosis rate was 3.10%. The early apoptosis rate of 180 μmol/L treatment group was 18.67%, and the late apoptosis rate was 5.20%. The early apoptosis rate of 270 μmol/L treatment group was 20.51%, and the late apoptosis rate was 10.23%. It can be seen that with the increase of drug concentration, the number of apoptotic cells also increased, and the number of late apoptotic cells also increased synchronously. It shows that with the increase of Isorhamnetin concentration, its effect on A549 cells gradually changes from proliferation inhibition to direct killing, and the higher the concentration, the more obvious the effect (Fig. 5A-D). This is also consistent with the results of cell morphology observation, indicating that isorhamnetin can induce apoptosis of A549 cells. PI staining was used to detect the effect of isorhamnetin on the cell cycle of A549 cells. The results showed that the proportion of G1 phase cells in the blank group was 63.17%, while the proportion of G1 phase cells in the 90, 180 and 270 μmol/L groups was 77.73%, 83.49% and 90.92%, respectively. It can be seen that with the increase of drug concentration, the G1 phase arrest is more obvious (Fig. 5E-H). This result further indicated thatA549 cells were arrested in G1 phase, and the process of DNA synthesis and cell division became slower with the increase of drug concentration. It is suggested that isorhamnetin can inhibit DNA replication and promote cell apoptosis, thereby reduce the rate of cell proliferation and controlling tumor diseases. Western blot The results of Western blot showed that there was no significant difference in the expression of AKT and PI3K between the blank group and each treatment group (P > 0.05), while the expression of P-AKT and P-PI3K decreased with the increase of drug concentration. Compared with the blank group, there was no statistical significance in the 90 μmol/L group,but there was statistical significance in the 180 and 270 μmol/L groups (P < 0.05) (Fig. 5I-K). From the previous theoretical analysis, it can be seen that the PI3K-Akt signaling pathway has a regulatory effect on a series of biological processes such as proliferation, apoptosis and migration of tumor cells, and the two targets of PI3K and AKT are the core targets of the pathway. It can be seen from the results that the expression of P-PI3K and P-Akt in each treatment group decreased. Although there was no significant difference in the expression between the 90 μmol/L group and the blank group, but the expression decreased with the increase of drug concentration, showing a dose-dependent manner. It was further proved that isorhamnetin can regulate the PI3K-Akt signaling pathway by inhibiting AKT1 and PI3K phosphorylation, thereby inhibit cell growth and proliferation and promoting apoptosis. Discussion Lung cancer is the malignant tumor with the highest mortality rate. As one of the main first-line treatment options, chemotherapy has the disadvantages of poor prognosis and toxic and side effects. Therefore, it is of great significance to explore ways to improve the efficacy and reduce the toxicity of chemotherapy for the treatment of NSCLC. As a traditional disease treatment plan in China, TCM has the characteristics of multi-component, multi-target and multi-channel synergistic treatment of diseases, and has many clinical applications in the treatment of malignant tumors. In this study, firstly, three core TCMs for the treatment of NSCLC were screened out by frequency statistics, association rules and cluster analysis. The frequency of these three Chinese medicines in the collected 269 clinical prescriptions was greater than 100, and the HQ reached 175 times, indicating their importance in the treatment of NSCLC. The results of association rule analysis also showed that the frequency of any two simultaneous occurrence of these TCMs was greater than 70, and the frequency of simultaneous occurrence of three TCMs was 52 times. Through cluster analysis, it was found that they were clustered into the same category, indicating that these TCMs have a strong correlation. Among them, HQ has the effects of tonifying qi, consolidating the exterior, diuresis and detoxification. It mainly contains Astragalus polysaccharides, saponins and flavonoids. Zhou et al. ' s research showed that various extracts of HQ had inhibitory effects on breast cancer cells, and can induce apoptosis and regulate PI3K/AKT/mTOR signaling pathway (Zhou et al. 2018 ). BZ has the functions of invigorating spleen and replenishing qi, drying dampness and promoting diuresis. The components of BZ include volatile oils, polysaccharides, lactones, vitamins, amino acids, etc. Chen et al. ' s research shows that various components extracted from BZ can induce apoptosis of colorectal cancer cells (Chen et al. 2023 ). Poria cocos has the effect of promoting water and dampness, invigorating spleen and calming heart. It contains polysaccharides, triterpenoids, sterols and other components. In this study, the anti-NSCLC mechanism of these three TCMs was further analyzed by network pharmacology. Through the PPI network, it can be found that various components of these three TCMs play an anti-NSCLC role through numerous targets, and the core targets EGFR and AKT1 were also screened (Miriam et al. 2024; Chen et al. 2023 ; Gao et al. 2023 ; Miller et al. 2024). It is reported that the mutation rate of EGFR in Asian NSCLC patients is as high as 50% (Attili et al. 2020 ). The abnormal activation of PI3K-Akt signaling pathway is one of the most common mechanisms of EGFR-TKIs resistance (Wang et al. 2016 ). However, there is still a lack of effective treatment for EGFR-TKIs resistance mediated by abnormal activation of PI3K-Akt signaling pathway (Tan, 2020 ). AKT1 is an important target in the PI3K-Akt signaling pathway. It is regulated by PI3K and PTEN. Its abnormal activation will promote tumor cell invasion, migration, proliferation and anti-apoptosis. After activation, PI3K accumulates on the cell membrane and phosphorylates 3,4-diphosphate phosphatidylinositol (PIP2) to 3,4,5-triphosphate phosphatidylinositol (PIP3) (Tiwari et al. 2017 ). PIP3 binds to AKT and activates Thr308 and Ser473 sites. The activated AKT then activates the mTOR signaling pathway, regulates protein synthesis and cell growth, promotes cell proliferation, and inhibits apoptosis. PTEN is the first known tumor suppressor gene with phosphatase activity. It antagonizes PI3K and inhibits AKT activation by promoting dephosphorylation of PIP3 at D3 to generate PIP2(Li et al. 2016 ). The results of KEGG enrichment analysis showed that EGFR tyrosine kinase inhibitor resistance and PI3K-Akt signaling pathway, which are closely related to EGFR and AKT1, were significantly enriched. It also proved that there was a strong correlation between the three traditional Chinese medicines screened in the previous study and the enriched targets and pathways. They may form a network of mutual synergy and interaction through these targets and pathways, thus playing a therapeutic role in NSCLC. The results of GO enrichment analysis also prove this point. The experimental results of CCK-8 showed that the three core components of quercetin, kaempferol and isorhamnetin screened in this study all had anti-NSCLC activity in a concentration-dependent and time-dependent manner, and isorhamnetin had the best inhibitory effect. Combined with scratch test and transwell test, it can be seen that isorhamnetin not only inhibits the proliferation, but also inhibits migrate and invade ability of A549 cells. It can be seen from the flow cytometry results that isorhamnetin inhibits the proliferation of A549 cells in two aspects: on the one hand, it promotes apoptosis, and on the other hand, it mediates cell cycle arrest. The rapid proliferation and metastasis of tumor cells are closely related to the disease progression of patients. If the proliferation and metastasis of tumor cells are inhibited, the speed and risk of deterioration of patients can be reduced. In order to verify whether isorhamnetin acts on A549 cells through the PI3K-Akt signaling pathway, this study performed Western blot experiments on PI3K and AKT, two key targets of the PI3K-Akt signaling pathway. PI3K has three expression types, among which PI3KI is most associated with the occurrence and development of cancer (Fruman et al. 2017 ). It can phosphorylate PIP2 to PIP3, and then transfer Akt to the plasma membrane to activate it. Akt contains three homologous genes: Akt1, Akt2 and Akt3.After activation, it will further activate its downstream target proteins to mediate the growth, invasion, metastasis and anti-apoptosis of tumor cells (Revathidevi et al. 2019 ). From the experimental results, it can be seen that the P-AKT/AKT and P-PI3K/PI3K in the treatment group were significantly lower than those in the control group, indicating that the AKT phosphorylation process was inhibited by isorhamnetin, indicating that the PI3K-Akt signaling pathway is one of the mechanisms by which isorhamnetin inhibits A549 cells. From the results of KEGG and GO enrichment analysis, it can be seen that the inhibitory mechanism of the core traditional Chinese medicine screened in this study on NSCLC is not only related to the PI3K-Akt signaling pathway, but also the active components of these three traditional Chinese medicines against NSCLC are not only quercetin, kaempferol and isorhamnetin. In the existing reports, they also have many components with anti-tumor activity (Yang et al. 2024 ; Zhang et al. 2023 ; Qiao et al. 2023 ; Xie et al. 2024 ). Therefore, further research on these anti-tumor active drugs is needed to screen out more anti-tumor active components for new drug development and clinical application. Conclusion In this study, the medication rules of 269 prescriptions for the treatment of NSCLC were analyzed. The results showed that the frequency of HQ, BZ and FL was higher than 100, and the association rule analysis also showed that they were highly correlated and clustered into the same category in cluster analysis, indicating that they had potential synergistic effects in the treatment of NSCLC and might be the core Chinese medicine for the treatment of NSCLC. In this study, 116 potential targets of these three core TCMs for NSCLC were collected. Through PPI network construction and mapping relationship between components and targets, we found out three key components of these three TCMs, quercetin, kaempferol and isorhamnetin, as well as the core targets AKT1 and EGFR for the treatment of NSCLC. Molecular docking verified that they could be stably combined; at the same time, through enrichment analysis, it was found that the mechanism of these three Chinese medicines in the treatment of NSCLC may be related to the PI3K-Akt pathway. Subsequent cell experiments further proved that Quercetin, Kaempferol and Isorhamnetin all had the effect of inhibiting A549 cells, and Isorhamnetin had the best effect. Isorhamnetin also inhibited the proliferation, migration and invasion of A549 cells, induced apoptosis and cell cycle arrest, and inhibited the phosphorylation of AKT1 and PI3K. Declarations Author contributions Qian Tang & Xuefang Zheng：Conceptualization, Funding acquisition, Project administration, Writing-review & editing. Yu Tang：Methodology, Investigation, Writing-original draft, Preparation, Writing-review & editing. Zhengping Xian：Investigation, Preparation, Technical supports, Writing-review & editing. Fengjiao Wu：Technical supports. Hongyu Cao：Software, Writing-review & editing. Lihao Wang：Writing-review & editing. Yanan Du：Writing-review & editing. The authors declare that all data were generated in-house and that no paper mill was used. Funding This work was financially supported by the National Natural Science Foundation of China (NO. 21571025，No.21601024，No.21601025), the subject construction project-the interdisciplinary project of Dalian University (DLUXK-2023-YB-007). Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Competing interests The authors declare no competing interests. Ethical approval Not applicable. References Acharya B et al (2022) β-Eudesmol Inhibits the Migration of Cholangiocarcinoma Cells by Suppressing Epithelial-Mesenchymal Transition via PI3K/AKT and p38MAPK Modulation. Asian Pac J Cancer Prev 23(8):2573-2581 Attili I et al (2020) Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way. Ann Transl Med 8(17): 1111 Bray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229-263 Chen H et al (2023) Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations. J Med Chem 66(17): 11656-11671 Chen LX et al (2024) Yi Qi Chu Tan Formula (YQCTF) inhibited the progress of lung cancer via regulating tumor-associated neutrophil: An integrated study of network pharmacology, proteomics and pharmacodynamics. J Ethnopharmacol 318(Pt B): 116943 Chen TQ et al (2023) Six polyacetylenes from Atractylodes macrocephala Koidz and their anti-colon cancer activity. Fitoterapia 167, 105490 Chen XM et al (2019) Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-γ. Front Pharmacol 10, 898 Dou SH et al (2021) Atractylenolide II induces cell cycle arrest and apoptosis in breast cancer cells through ER pathway. Pak J Pharm Sci 34(4):1449–1458 Fei MH et al (2023) Effects of Modified Baizhu Shaoyao San on Postoperative Diarrhea in Colorectal Cancer Patients: A Single-Blind, Randomized Controlled Trial. Complement Med Res 30(1):37–44 Fruman D. A et al (2017). The PI3K Pathway in Human Disease. Cell 170(4):605–635 Gao HL et al (2023) The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells. Front Pharmacol 14:1235285 Garon E. B et al (2019). Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol 37(28):2518–2527 He Y et al (2021) Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6(1):425 He ZQ et al (2024) Anticancer Mechanism of Astragalus Polysaccharide and Its Application in Cancer Immunotherapy. Pharmaceuticals (Basel) 17:5 636 Jiang F et al (2023) Pachymic Acid Inhibits Growth and Metastatic Potential in Liver Cancer HepG2 and Huh7 Cells. Biol Pharm Bull 46(1):35–41 Jiménez J et al (2017) DeepSite: protein-binding site predictor using 3D-convolutional neural networks. Bioinformatics 33(19):3036–3042 Khezri M. R et al (2022) The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions. Exp Mol Pathol 127: 104787 Li SJ. J et al (2016) Wogonin induces Beclin-1/PI3K and reactive oxygen species-mediated autophagy in human pancreatic cancer cells. Oncol Lett 12(6):5059–5067 Long XM et al (2023) Network-based Pharmacology and In vitro Validation Reveal that Galangin Induces Apoptosis in Bladder Cancer Cells by Promoting the P53 Signaling Pathway. Anticancer Agents Med Chem 23(7):847–857 Mao JJ et al (2022) Effects of Atractylon on Proliferation and Apoptosis of Intestinal Cancer Cells Through PI3K/AKT/mTOR Signaling Pathway. Cell Mol Biol (Noisy-le-grand) 68(5):153–160 Miriam Dorta-Suárez et al (2024) The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives. Cancer Treat Rev 124: 102671 Miller Karina A et al (2024) PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression. Oncogene 43(1):22-34 Peng L et al (2020) Anti-cancer activity of Conyza blinii saponin against cervical carcinoma through MAPK/TGF-β/Nrf2 signaling pathways. J Ethnopharmacol 251:112503 Qiao PF et al (2023) Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27. Front Oncol 6(12):1084884 Revathidevi S et al (2019) Akt in cancer: Mediator and more. Semin Cancer Biol 59:80–91 St Claire S et al (2020) Lung health, tobacco, and related products: gaps, challenges, new threats, and suggested research. American journal of physiology. Am J Physiol Lung Cell Mol Physiol 318(5): L1004–L1007 Tan A. C (2020) Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer 11(3):511–518 Tiwari V et al (2017) Akt1/NFκB signaling pathway activation by a small molecule DMA confers radioprotection to intestinal epithelium in xenograft model. Free Radic Biol Med 108:564–574 Wang J et al (2016) Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther 9:3711–3726 Wang YS et al (2020) Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomed Pharmacother 121:109570 Wei JR et al (2024) Lianhua Qingwen exerts anti-liver cancer effects and synergistic efficacy with sorafenib through PI3K/AKT pathway: Integrating network pharmacology, molecular docking, and experimental validation. Gene 912:148383 Xiao ZW et al (2021) Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer: A randomized, controlled trial. Medicine (Baltimore) 100 (18): e25690 Xie ZN et al (2024) Insights into the inhibition of stomach cancer MKN45 cell growth by Poria cocos ethanol-soluble extract based on MAPK/PI3K signaling pathways and components cell fishing. J Ethnopharmacol 10 (320):117417 Xu F et al (2018) Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling. J Exp Clin Cancer Res 37(1):207 Xu HC et al (2021) Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. J Clin Invest 131(10):e146832 Yang Q et al (2024) Advances in research on the anti-tumor mechanism of Astragalus polysaccharides. Front Oncol 14:1334915 Yang RY et al (2024) Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis. Phytomedicine 122: 155135 Yin YF et al (2022) Icariin Regulates the hsa_circ_0003159/eIF4A3/bcl-2 Axis to Promote Gastric Cancer Cell Apoptosis. Evid Based Complement Alternat Med 2022:1955101 Yu L et al (2022) Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol 85:69–94 Zhang D et al (2022) Atractylenolide III induces apoptosis by regulating the Bax/Bcl-2 signaling pathway in human colorectal cancer HCT-116 Cells in vitro and in vivo. Anticancer Drugs 33(1):30–47 Zhang LJ et al (2023) Astragaloside II enhanced sensitivity of ovarian cancer cells to cisplatin via triggering apoptosis and autophagy. Cell Biol Int 47(9):1600-1613 Zhang XY et al (2022) Clinical study on Yanghe decoction in improving neo-adjuvant chemotherapy efficacy and immune function of breast cancer patients. Medicine (Baltimore) 101(10):e29031 Zhang YM et al (2019) The Effects of Astragalus Polysaccharide on Bone Marrow-Derived Mesenchymal Stem Cell Proliferation and Morphology Induced by A549 Lung Cancer Cells. Med Sci Monit 25:4110–4121 Zhang ZP et al (2024) Modified Banxiaxiexin decoction benefitted chemotherapy in treating gastric cancer by regulating multiple targets and pathways. J Ethnopharmacol 331: 118277 Zhao WJ et al (2024) Si Jun Zi decoction inhibits the growth of lung cancer by reducing the expression of PD-L1 through TLR4/MyD88/NF-κB pathway. J Ethnopharmacol 318(Pt A):116948 Zheng RS et al (2022) Cancer incidence and mortality in China, 2016. JNCC 2 (1):1-9. Zhou RJ et al (2018) Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway. BMC Complement Altern Med 18(1):83 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 29 Jul, 2024 Read the published version in Naunyn-Schmiedeberg's Archives of Pharmacology → Version 1 posted Editorial decision: Revision requested 12 Jul, 2024 Reviews received at journal 11 Jul, 2024 Reviews received at journal 07 Jul, 2024 Reviewers agreed at journal 05 Jul, 2024 Reviewers agreed at journal 03 Jul, 2024 Reviewers agreed at journal 30 Jun, 2024 Reviewers invited by journal 30 Jun, 2024 Editor assigned by journal 28 Jun, 2024 Submission checks completed at journal 28 Jun, 2024 First submitted to journal 27 Jun, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4648678","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":326351476,"identity":"ae1265e0-fb2d-4ff0-b2dc-976d5484aedc","order_by":0,"name":"Qian Tang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA10lEQVRIiWNgGAWjYNACAwYGfobkBiCLmbBiHpgWyYZEkrSAdB0gVos9+9nDL94U2OUZH09sk2CosE5sYD97AL8tPHlplnMMkovNzjwEajmTntjAk5dAwGE5ZsY8BsyJ224AbWFsO5zYIMFjgF8L/xuQlvrEzTNAWv4Ro0Uix/gxj8HhxA0SIC0NxGi58caMcY7B8cQZZx42WyQcSzdu48nBr4W9P8f4w5s/1Yn97ckHb3yosZbtZz+DXwsQsEnAIycBxCWkHgiYP/AQVjQKRsEoGAUjGQAAxnlDRTMcUG0AAAAASUVORK5CYII=","orcid":"","institution":"College of Life and healthy, Dalian University, Dalian 116622","correspondingAuthor":true,"prefix":"","firstName":"Qian","middleName":"","lastName":"Tang","suffix":""},{"id":326351477,"identity":"58c1284d-4004-4c75-9d16-938878793bbc","order_by":1,"name":"Xuefang Zheng","email":"","orcid":"","institution":"Liaoning Key Laboratory of Bio-Organic Chemistry, Dalian University, Dalian 116622","correspondingAuthor":false,"prefix":"","firstName":"Xuefang","middleName":"","lastName":"Zheng","suffix":""},{"id":326351478,"identity":"eb0a04e3-51c9-413a-aa2a-5f0665bae9b8","order_by":2,"name":"Yu Tang","email":"","orcid":"","institution":"College of Life and healthy, Dalian University, Dalian 116622","correspondingAuthor":false,"prefix":"","firstName":"Yu","middleName":"","lastName":"Tang","suffix":""},{"id":326351479,"identity":"755dc65b-494a-4576-afb8-5db190ffce4a","order_by":3,"name":"Zhengping Xian","email":"","orcid":"","institution":"College of Life and healthy, Dalian University, Dalian 116622","correspondingAuthor":false,"prefix":"","firstName":"Zhengping","middleName":"","lastName":"Xian","suffix":""},{"id":326351480,"identity":"32739924-25a0-4c1b-8621-ad47c5290101","order_by":4,"name":"Fengjiao Wu","email":"","orcid":"","institution":"College of Life and healthy, Dalian University, Dalian 116622","correspondingAuthor":false,"prefix":"","firstName":"Fengjiao","middleName":"","lastName":"Wu","suffix":""},{"id":326351481,"identity":"1b3611ee-bcda-4b1c-a5be-b2ea5e8670f9","order_by":5,"name":"Hongyu Cao","email":"","orcid":"","institution":"College of Life and healthy, Dalian University, Dalian 116622","correspondingAuthor":false,"prefix":"","firstName":"Hongyu","middleName":"","lastName":"Cao","suffix":""},{"id":326351482,"identity":"5c8fa66a-487a-4ed8-9789-1cd1c982e5b9","order_by":6,"name":"Yanan Du","email":"","orcid":"","institution":"College of Environmental and Chemical Engineering, Dalian University, Dalian 116622","correspondingAuthor":false,"prefix":"","firstName":"Yanan","middleName":"","lastName":"Du","suffix":""}],"badges":[],"createdAt":"2024-06-27 12:56:14","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4648678/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4648678/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s00210-024-03310-5","type":"published","date":"2024-07-29T15:57:35+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":60693882,"identity":"cca2bc1d-6f5c-456e-94ad-c16bc7910183","added_by":"auto","created_at":"2024-07-19 15:43:17","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":1254026,"visible":true,"origin":"","legend":"\u003cp\u003eGraphical abstract\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-4648678/v1/05c176822a3de70e7bd61880.png"},{"id":60694817,"identity":"51477b93-4022-4892-908c-072d9c192d2e","added_by":"auto","created_at":"2024-07-19 15:59:17","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":927846,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eA\u003c/strong\u003e High frequency herbs (top 10). \u003cstrong\u003eB\u003c/strong\u003e Cluster analysis. \u003cstrong\u003eC\u003c/strong\u003e Herbs and NSCLC intersection targets. \u003cstrong\u003eD\u003c/strong\u003ePPI network of herbal anti-NSCLC. \u003cstrong\u003eE\u003c/strong\u003e KEGG enrichment analysis of herbal anti-NSCLC targets (top 15).\u003cstrong\u003e F\u003c/strong\u003e GO enrichment analysis of herbal anti-NSCLC targets (top 15). \u003cstrong\u003eG\u003c/strong\u003e Components-targets-PI3K/Akt signaling pathway. \u003cstrong\u003eH\u003c/strong\u003e Molecular docking results (EGFR-Isorhamnetin)\u003c/p\u003e","description":"","filename":"floatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-4648678/v1/41dc50a97a16e53a69d01671.png"},{"id":60693881,"identity":"e9e1d6ee-f3cc-4101-8def-27b014732fd5","added_by":"auto","created_at":"2024-07-19 15:43:17","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":458828,"visible":true,"origin":"","legend":"\u003cp\u003eCell viability and morphology observation. Effects of Quercetin, Kaempferol and Isorhamnetin on the viabilityof A549 cell, \u003cstrong\u003eA\u003c/strong\u003e 24h. \u003cstrong\u003eB\u003c/strong\u003e 48h. \u003cstrong\u003eC\u003c/strong\u003e 72h. \u003cstrong\u003eD\u003c/strong\u003eThe effect of Isorhamnetinon the viability of A549 cells at 24,48 and 72 h. Effect of isorhamnetin on the morphology of A549 cells, inverted microscope (E, F), confocal microscopy (G, H)\u003cstrong\u003eE\u003c/strong\u003e Control group. \u003cstrong\u003eF\u003c/strong\u003e Treatment group\u003cstrong\u003e,\u003c/strong\u003e \u003cstrong\u003eG \u003c/strong\u003eControl group, \u003cstrong\u003eH\u003c/strong\u003e Treatment group\u003c/p\u003e","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-4648678/v1/926d4ea8929f73d9e55b90d2.png"},{"id":60694269,"identity":"249cde15-cb4c-4c93-866c-ab3031f37292","added_by":"auto","created_at":"2024-07-19 15:51:17","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":802929,"visible":true,"origin":"","legend":"\u003cp\u003eEffect of Isorhamnetinon migration of A549 cells, 0 h: \u003cstrong\u003eA\u003c/strong\u003e-\u003cstrong\u003eD\u003c/strong\u003e (0, 90, 180, 270 μmol/L); 48h: \u003cstrong\u003eE\u003c/strong\u003e-\u003cstrong\u003eH\u003c/strong\u003e (0, 90, 180, 270 μmol/L); \u003cstrong\u003eE-H\u003c/strong\u003e Cell cycle (0, 90,180, 270 μmol/L). Effect of Isorhamnetin on invasion of A549 cells, \u003cstrong\u003eI\u003c/strong\u003e-\u003cstrong\u003eL\u003c/strong\u003e (0, 90, 180, 270 μmol/L); \u003cstrong\u003eM\u003c/strong\u003eCell migration statistics;\u003cstrong\u003e N\u003c/strong\u003e Cell invasion statistics. **\u003cem\u003eP\u003c/em\u003e ＜ 0.05，**\u003cem\u003eP\u003c/em\u003e ＜ 0.01，***\u003cem\u003e P\u003c/em\u003e ＜ 0.001 vs. control group\u003c/p\u003e","description":"","filename":"floatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-4648678/v1/6ab5a61f07d22e54ba5fc4c0.png"},{"id":60694816,"identity":"47e64110-445f-450c-805e-6bb5b1d35e91","added_by":"auto","created_at":"2024-07-19 15:59:17","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":566489,"visible":true,"origin":"","legend":"\u003cp\u003eEffects of isorhamnetin on apoptosis, cell cycle and protein expression of PI3K-AKt pathway in A549 cells. \u003cstrong\u003eA-D\u003c/strong\u003e Apoptosis (0, 90, 180, 270 μmol/L); \u003cstrong\u003eE-H\u003c/strong\u003e Cell cycle (0, 90, 180, 270 μmol/L);\u003cstrong\u003e I\u003c/strong\u003e Western blot results, \u003cstrong\u003eJ\u003c/strong\u003e PI3K expression statistics, \u003cstrong\u003eK\u003c/strong\u003e Akt expression statistics. **\u003cem\u003eP\u003c/em\u003e ＜ 0.01，***\u003cem\u003e P\u003c/em\u003e ＜ 0.001 vs. control group\u003c/p\u003e","description":"","filename":"floatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-4648678/v1/c6ab266652b30efe00dd09c0.png"},{"id":61793450,"identity":"07423722-5183-4bed-af94-9b3710796c46","added_by":"auto","created_at":"2024-08-05 16:12:41","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":5216229,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4648678/v1/99fdbdd8-730b-420d-85be-dcc5bb2c47f6.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: Key drug screening and mechanism analysis","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAccording to the report of the International Agency for Research on Cancer (IARC), the incidence (12.4 %) and mortality (18.7 %) of lung cancer in 2022 rank first (Bray et al. 2024), while the report of the National Cancer Center of China also shows that in 2022, China \u0026apos;s lung cancer will increase by 1.06 million and die by 730,000, which is also the cancer with the highest incidence and mortality (Zheng et al. 2022). Pathologically, lung cancer can be divided into small cell lung cancer and non-small cell lung cancer. NSCLC accounts for 80% - 85%, and 75% of patients are diagnosed at an advanced stage (St et al. 2020), which will make the patients miss the best treatment stage, so the 5-year survival rate of NSCLC patients is only 5.5% (Garon et al. 2019). At present, chemotherapy is one of the main treatment methods for NSCLC, but the survival rate of patients with advanced lung cancer receiving traditional chemotherapy is very low, and adverse reactions such as bone marrow suppression, liver and kidney function damage, and alopecia often occur, which seriously affects the quality of life of patients. Therefore, the methods of how to improve the therapeutic effect, patient survival rate and reduce adverse reactions are particularly important.\u003c/p\u003e\n\u003cp\u003eAs a traditional Chinese disease treatment plan, TCMs has the advantages of small side effects, non-invasiveness, low cost, and wide benefit population in tumor treatment. In recent years, many studies have shown that a variety of TCM components have anti-tumor activity (Chen et al. 2024; Yin et al. 2022; Yang et al. 2024), and the effect of reducing toxicity and increasing efficacy in the process of combined treatment with other treatment regimens is obvious. The multi-channel and multi-target treatment characteristics of TCMs can make up for the shortcomings of the current first-line treatment plans, such as single action pathway and large toxic and side effects. For example, Xiao et al. (Xiao et al. 2021) randomly divided 39 patients with stage III~IV NSCLC into TCM (Includes traditional Chinese medicine injection, traditional Chinese medicine decoction, capsule) combined with chemotherapy group and chemotherapy alone group. The results showed that the quality of life (QOL) score of the combined treatment group was higher, and the incidence of thrombocytopenia was significantly lower than that of the control group. There are also a number of studies that show that TCM has the effect of reducing toxicity and increasing efficiency (Wei et al. 2024; Zhang et al. 2022; Fei et al. 2023). Although modern pharmacological studies have shown that TCM can regulate TLR4/MyD88/NF-\u0026kappa;B, P53, MAPK/TGF-\u0026beta;/Nrf2 and other signaling pathways (Zhao et al. 2024; Peng et al. 2020; Long et al. 2023), it can inhibit tumor proliferation, invasion and angiogenesis, so as to enhance drug sensitivity, reverse drug resistance, reduce adverse reactions and toxicity, and improve patient immunity (Zhang et al. 2024; Wang et al. 2020). However, due to the large number of components and targets of TCM, and the complex anti-tumor mechanism, and many components and mechanisms of action are not still clearly explained. Therefore, it is necessary to conduct in-depth research on it. In this study, the clinical randomized controlled literature of traditional Chinese medicine decoction combined with chemotherapy in the treatment of advanced NSCLC was excavated, and the prescriptions of traditional Chinese medicine were collected. The core TCM was screened out by frequency statistics, association rule analysis and cluster analysis. After that, the key targets and pathways of core TCM in the treatment of NSCLC were screened by network pharmacology analysis, and the key components were screened. In the end, they were verficated through molecular docking and cell experiment, to the results will provide reference for the treatment of NSCLC with TCM and the development of new drugs.\u003c/p\u003e"},{"header":"Materials and methods","content":"\u003cp\u003e\u003cstrong\u003eMaterials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eQuercetin, Kaempferol, CCK-8 kit were purchased from Aladdin (Shanghai, China); Isorhamnetin was purchased from Alfabiotech (Chengdu, China); Annexin V-FITC Apoptosis Detection Kit, Cell Cycle and Apoptosis Analysis Kit, Cell Plasma Membrane Staining Kit with DiO, Extracellular Matrix were purchased from Beyotime (Shanghai, China); PI, Recombinant Anti-GAPDH antibody, Prestained Protein Marker Ⅶ were purchased from Servicebio; Transwell chamber was purchased from NEST (Wuxi, China); Rabbit anti-PI3K, Rabbit anti-Phosphorylated PI3K, Goat Anti-Rabbit IgG were purchased from ZEN-BIOSCIENCE (Chengdu, China); Rabbit anti-AKT, Rabbit anti-Phosphorylated AKT were purchased from Proteintech (Wuhan, China); A549 cell line from ATCC (US).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRetrieval methodology\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026apos;Chinese traditional medicine \u0026apos;, \u0026apos; non-small cell lung cancer \u0026apos;, \u0026apos; NSCLC \u0026apos;, and \u0026apos; chemical therapy \u0026apos; were used as keywords to search CNKI, WanFang, VIP, Pubmed, Web of Science. The search date was from the establishment of the database to October 20, 2023.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLiterature\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;inclusion and exclusion criteria\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eInclusion criteria:\u0026nbsp;①Type of study: RCT study;\u0026nbsp;②Subjects: patients with stage III~IV NSCLC diagnosed by histopathology and cytology;\u0026nbsp;③Intervention measures : the control group was only treated with conventional chemotherapy, and the experimental group was treated with traditional Chinese medicine decoction orally on the basis of the control group.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eExclusion criteria:\u0026nbsp;①review, cell or animal test literature;\u0026nbsp;②subjects with other diseases, TNM stage I~II;\u0026nbsp;③Literatures on other western medicine treatment methods other than chemotherapy or other traditional Chinese medicine treatment methods other than oral Chinese medicine decoction were used in the experiment;\u0026nbsp;④The composition of the drugs in the prescription is unknown.\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData extraction and collation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe included prescriptions were sorted into the Excel table. If the literature contained multiple prescriptions, the multiple prescriptions would be included in the statistics separately. Due to the dialectical medication, the addition and subtraction on the basic side only recorded the basic side, and finally removed the repeated prescription. For the same TCM, if there are different drug names, it is unified as the only drug name; for the same TCM due to the use of different parts, origin, processing methods and have different effects are recorded respectively.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMedication rule analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe collected prescriptions of TCMs were used for frequency statistics to find out high-frequency drugs; then the association rule analysis and cluster analysis were carried out through the \u0026apos; arules \u0026apos; and \u0026apos; fmsb \u0026apos; packages of R language. The association rules were screened with support \u0026gt; 0.1 and confidence \u0026gt; 0.6, and the core drugs of TCM for NSCLC were screened according to the results.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTargets collection\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe components of core drugs (OB \u0026gt; 30 %, DL \u0026gt; 0.18) were collected through TCMSP (https://tcmspw.com/tcms-p.php) database), and the components with antitumor activity confirmed by existing experiments but not included in TCMSP were supplemented by literature review. The potential targets of the collected components were collected through the SwissTargetPrediction (http:// www.swisstargetprediction.ch/) database (Probability \u0026gt; 0.15).\u003c/p\u003e\n\u003cp\u003eNSCLC targets were collected from OMIM (https://www.omim.org/), GeneCards (https://www.genecards.org/), DisGeNET (https://www.disgenet.org/) and TTD (https://db.idrblab.net/ttd/) databases with the keyword \u0026apos; non-small cell lung cancer \u0026apos;. The collected potential drug targets and NSCLC targets were deduplicated and intersected to obtain potential targets for drug treatment of NSCLC.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePPI network construction\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe intersection targets were input into the STRING (https://cn.string-db.org/) database, and the species was set to \u0026apos; Homo sapiens \u0026apos;, with the minimum action threshold \u0026gt; 0.4. The obtained PPI network was imported into Cytoscape 3.9.1, and the core targets were screened according to degree, betweenness centrality and closeness centrality, then the results were visualized.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEnrichment analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eGO and KEGG analysis were performed through the \u0026apos; Bioconductor \u0026apos; package of R language to screen out the key pathways of key Chinese medicine in the treatment of NSCLC and visualize them.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMolecular docking\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe protein structures of AKTI (PDB ID: 4ekl) and EGFR (PDB ID: 6lub) were obtained from PDB (https://www.rcsb.org/) database, and the active pockets of target proteins were predicted by DeepSite (https://playmolecule.com/) platform)\u0026nbsp;(Jim\u0026eacute;nez et al. 2017). The protein was subjected to dehydration and hydrogenation by Pymol 2.6.0a0, and then molecular docking was performed by AutoDock 1.5.7.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eA549 cell culture\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe cells were cultured in F12K medium containing 10% fetal bovine serum at 37 \u0026deg;C, 5% CO\u003csub\u003e2\u003c/sub\u003e, and the medium was changed once a day. The cells were passaged when the degree of fusion reached 80%.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDetermined by cell viability assay\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe cell viability was detected by CCK-8 method. A549 cells were inoculated in 96-well plates at 5000 cells / well, with 5 replicate wells in each group. After the cells adhered to the wall, Quercetin, Kaempferol and Isorhamnetin were mixed with a concentration gradient of 0, 50, 100, 150, 200, 250 and 300 \u0026mu;mol/L for intervention, and the cell viability was detected at 24, 48 and 72 h, respectively. 100 \u0026mu;L CCK-8 working solution was added to each well for detection. After incubation for 30 min at 37 \u0026deg;C in dark, the OD value at 450 nm was detected by microplate reader, and the maximum and minimum values of each group were removed. Cell viability = (experimental OD-blank OD) / (control OD-blank OD) \u0026times; 100%. Finally, the components with the best inhibitory effect were selected for subsequent experiments.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCell morphology observation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA549 cells were inoculated on polylysine-treated slides and treated with 0 and 270 \u0026mu;mol / L for 48 h after cell attachment. Then, the cells were stained with Dio/PI staining solution (binding buffer: Dio: PI = 300: 1: 90), incubated for 20 min at 37 \u0026deg;C in the dark, the staining solution was removed, washed three times with PBS, and the cell morphology was observed under laser confocal microscopy.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCell migration\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe effect of isorhamnetin on the migration of A549 cells was verified by scratch test. A549 cells were inoculated in a 6-well plate to make the overnight fusion rate reach 100 %. The scratches were scratched with a 10 \u0026mu;L pipette tip, and then PBS was used to wash away the cell debris. The drug was prepared into 0, 90, 180, 270 \u0026mu;mol/L with F12 K medium containing 1% fetal bovine serum. After 48 h of treatment, the cell migration rate of each group was calculated. Cell migration rate = (0 h scratch area-48 h scratch area) / 0 h scratch area \u0026times; 100 %.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCell invasion\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe effect of isorhamnetin on the invasion ability of A549 cells was verified by transwell assay. The matrigel was prepared according to the kit instructions and added to the upper chamber. After digestion, the cells were made into cell suspension with complete medium containing 0, 90, 180, 270 \u0026mu;mol/L drugs, respectively, inoculated in the upper chamber and cultured for 24 h at 37 \u0026deg;C. The cells and matrigel in the upper chamber were wiped off with a cotton swab, fixed with tissue fixative for 10 min, stained with 0.4% crystal violet, and photographed under an inverted microscope.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eApoptosis and cell cycle\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe effects of isorhamnetin on apoptosis and cell cycle of A549 cells were detected by flow cytometry. Apoptosis: A549 cells were seeded in a 6-well plate and added to a complete medium containing 0, 90, 180, 270 \u0026mu;mol/L drugs after cell adherence. After culture of 48 h, cells were collected and stained with Annexin V-FITC and PI according to the kit instructions. After incubation of 20 min in the dark, the apoptosis was detected.\u003c/p\u003e\n\u003cp\u003eCell cycle arrest: Grouping and treatment methods are the same as apoptosis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eWestern blot\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe cells were treated with 0, 90, 180 and 270 \u0026mu;mol/L drugs, respectively. After 48 h, the total protein was extracted and quantified by BCA kit. The sample was loaded at 20 \u0026mu;g/well, and the protein was separated by SDS-PAGE electrophoresis at 200 V constant pressure and 400 mA constant flow membrane. BSA was blocked for 2 h, the primary antibody was incubated overnight at 4 \u0026deg;C, the secondary antibody was incubated at room temperature for 1 h, and the ECL developer was developed. The results were analyzed by Image J 1.54 f software.\u003c/p\u003e"},{"header":"Results and analysis","content":"\u003cp\u003e\u003cstrong\u003eLiterature retrieval results\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA total of 7714 articles were retrieved, including 2585 articles on CNKI, 3689 articles on Wanfang, 1142 articles on VIP, 60 articles on pubmed, and 238 articles on web of science. After removing the duplicate literature, the remaining 5310 articles were collected, 298 prescriptions were collected, finally, 269 prescriptions were remained after deleting the repeated prescriptions.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMedication rule analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA total of 295 traditional Chinese medicines were used from 269 prescriptions, and among them, the five most frequently used were HQ, FL, BZ, Ophiopogon japonicus (MD, in Chinese), Glycyrrhiza uralensis (GC, in Chinese) (Fig. 2A); the three drug pairs of BZ-HQ, Hedyotis diffusa(BHSSC, in Chinese)-HQ and BZ-FL were ranked the highest in support, and they were also the most frequently used in the analysis of association rules (Table1). After clustering analysis of TCMs, it was found that Codonopsis pilosula(DS, in Chinese), HQ, BZ and FL were clustered into the same category, which indicated that these TCMs have similar properties and functions (Fig. 2B). Due to the highest frequency and correlation of HQ, BZ and FL based on the above analysis results, they were selected as the core drugs for subsequent analysis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 1\u003c/strong\u003e Correlated herb pairs (top 10)\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"255\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003ecouplet drugs\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.265625%\"\u003e\n \u003cp\u003esupport\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003econfidence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.359375%\"\u003e\n \u003cp\u003edegree\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003eBZ-HQ\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.265625%\"\u003e\n \u003cp\u003e0.29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003e0.74\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.359375%\"\u003e\n \u003cp\u003e79\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003eBHSSC-HQ\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.265625%\"\u003e\n \u003cp\u003e0.29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003e0.81\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.359375%\"\u003e\n \u003cp\u003e78\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003eBZ-FL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.265625%\"\u003e\n \u003cp\u003e0.29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003e0.72\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.359375%\"\u003e\n \u003cp\u003e77\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003eFL-HQ\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.265625%\"\u003e\n \u003cp\u003e0.29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003e0.66\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.359375%\"\u003e\n \u003cp\u003e77\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003eMD-HQ\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.265625%\"\u003e\n \u003cp\u003e0.28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003e0.68\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.359375%\"\u003e\n \u003cp\u003e74\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003eDS-HQ\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.265625%\"\u003e\n \u003cp\u003e0.27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003e0.71\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.359375%\"\u003e\n \u003cp\u003e72\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003eGC-HQ\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.265625%\"\u003e\n \u003cp\u003e0.26\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003e0.66\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.359375%\"\u003e\n \u003cp\u003e71\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003eDS-BZ\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.265625%\"\u003e\n \u003cp\u003e0.25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003e0.65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.359375%\"\u003e\n \u003cp\u003e66\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003eDS-FL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.265625%\"\u003e\n \u003cp\u003e0.23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003e0.62\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.359375%\"\u003e\n \u003cp\u003e63\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003eCP-FL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.265625%\"\u003e\n \u003cp\u003e0.18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.6875%\"\u003e\n \u003cp\u003e0.72\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.359375%\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e* CP (Tangerine Peel, in Chinese)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eNetwork Pharmacology Analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCore targets and component screening\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA total of 40 active ingredients of core drugs that met the screening conditions were collected from TCMSP, and 9 were supplemented through literature review\u0026nbsp;(Xu et al. 2018; Chen et al. 2019; Zhang et al. 2019; Dou et al. 2021; Xu et al. 2021; Acharya et al. 2022; Mao et al. 2022; Zhang et al. 2022; Jiang et al. 2023). The collected components were imported into the SwissTargetPrediction database, then 156 potential targets that met the screening conditions were obtained. A total of 1309,1490,3926 and 168 NSCLC targets were collected from GeneCards, OMIM, DisGeNET and TTD databases, respectively. After removing duplicate targets, 5549 NSCLC targets were obtained. After intersecting the potential targets of active ingredients and NSCLC targets, 116 intersection targets were obtained, that is, the potential targets of core TCM in the treatment of NSCLC (Fig. 2C). According to the intersection targets obtained above, three key components were screened by sorting the degree values of the components corresponding to these targets: Quercetin, Kaempferol and Isorhamnetin.\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePPI network construction\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2\u003c/strong\u003e Key targets of herbal medicine against NSCLC (top 10)\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"255\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.265625%\" valign=\"top\"\u003e\n \u003cp\u003eTarget\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.203125%\" valign=\"top\"\u003e\n \u003cp\u003eBetweenness\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5625%\" valign=\"top\"\u003e\n \u003cp\u003eCloseness\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.96875%\" valign=\"top\"\u003e\n \u003cp\u003eDegree\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.265625%\" valign=\"top\"\u003e\n \u003cp\u003eAKT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.203125%\"\u003e\n \u003cp\u003e1955.66\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5625%\"\u003e\n \u003cp\u003e0.01\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.96875%\"\u003e\n \u003cp\u003e65.00\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.265625%\" valign=\"top\"\u003e\n \u003cp\u003eEGFR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.203125%\"\u003e\n \u003cp\u003e1547.19\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5625%\"\u003e\n \u003cp\u003e0.01\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.96875%\"\u003e\n \u003cp\u003e60.00\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.265625%\" valign=\"top\"\u003e\n \u003cp\u003eESR1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.203125%\"\u003e\n \u003cp\u003e1281.93\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5625%\"\u003e\n \u003cp\u003e0.01\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.96875%\"\u003e\n \u003cp\u003e52.00\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.265625%\" valign=\"top\"\u003e\n \u003cp\u003ePTGS2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.203125%\"\u003e\n \u003cp\u003e1144.71\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5625%\"\u003e\n \u003cp\u003e0.01\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.96875%\"\u003e\n \u003cp\u003e46.00\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.265625%\" valign=\"top\"\u003e\n \u003cp\u003eSRC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.203125%\"\u003e\n \u003cp\u003e792.72\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5625%\"\u003e\n \u003cp\u003e0.01\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.96875%\"\u003e\n \u003cp\u003e46.00\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.265625%\" valign=\"top\"\u003e\n \u003cp\u003eMMP9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.203125%\"\u003e\n \u003cp\u003e356.01\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5625%\"\u003e\n \u003cp\u003e0.01\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.96875%\"\u003e\n \u003cp\u003e41.00\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.265625%\" valign=\"top\"\u003e\n \u003cp\u003eGSK3B\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.203125%\"\u003e\n \u003cp\u003e393.78\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5625%\"\u003e\n \u003cp\u003e0.01\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.96875%\"\u003e\n \u003cp\u003e37.00\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.265625%\" valign=\"top\"\u003e\n \u003cp\u003ePARP1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.203125%\"\u003e\n \u003cp\u003e498.49\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5625%\"\u003e\n \u003cp\u003e0.01\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.96875%\"\u003e\n \u003cp\u003e38.00\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.265625%\" valign=\"top\"\u003e\n \u003cp\u003eMCL1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.203125%\"\u003e\n \u003cp\u003e257.82\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5625%\"\u003e\n \u003cp\u003e0.01\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.96875%\"\u003e\n \u003cp\u003e32.00\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.265625%\" valign=\"top\"\u003e\n \u003cp\u003eKDR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.203125%\"\u003e\n \u003cp\u003e214.27\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5625%\"\u003e\n \u003cp\u003e0.01\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.96875%\"\u003e\n \u003cp\u003e32.00\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eThe 116 intersection targets were imported into the STRING database to obtain the PPI network. The obtained PPI network was analyzed by Cytoscape and the screening condition was greater than the mean value, that is, degree \u0026gt; 14.85, closeness centrality \u0026gt; 0.0042, betweenness centrality \u0026gt; 129.01. The key targets of TCMs components in the treatment of NSCLC were screened (Table 2). Because the degree, betweenness centrality and closeness centrality of EGFR and AKT1 were significantly higher than those of other targets, they were identified as the core targets of Astragalus, Atractylodes and Poria in the treatment of NSCLC (Fig. 2D). Then, they were molecularly docked with the three core components (Quercetin, Kaempferol and Isorhamnetin) screened above.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEnrichment analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA total of 110 KEGG signaling pathways were enriched, including PI3K-Akt signaling pathway, EGFR tyrosine kinase inhibitor resistance, FoxO signaling pathway and other signaling pathways closely related to malignant tumors (Fig. 2E). 1982 GO entries was enriched by GO functional enrichment, involving 1703 biological processes, 90 cellular components, and 189 molecular functions (Fig. 2F). According to the results of KEGG enrichment, both the significance and the number of enriched intersection targets are higher in the PI3K-Akt signaling pathway, and existing studies have also shown that it is closely related to tumors (He et al. 2021; Khezri et al. 2022; et al. 2022). Therefore, we will futher verify it by Western blot experiments. In addition, we plotted \u0026nbsp;the component-target-PI3K/Akt signaling pathway according to the corresponding relationship between PI3K-Akt pathway, targets and components (Fig. 2G).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMolecular docking\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3\u003c/strong\u003e Docking binding energy\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"255\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"34.11764705882353%\" valign=\"top\"\u003e\n \u003cp\u003eComponents\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.11764705882353%\" valign=\"top\"\u003e\n \u003cp\u003eAKT1\u003c/p\u003e\n \u003cp\u003ekcal/mol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.764705882352942%\" valign=\"top\"\u003e\n \u003cp\u003eEGFR\u003c/p\u003e\n \u003cp\u003ekcal/mol\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"34.11764705882353%\" valign=\"top\"\u003e\n \u003cp\u003eQuercetin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.11764705882353%\" valign=\"top\"\u003e\n \u003cp\u003e-6.53\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.764705882352942%\" valign=\"top\"\u003e\n \u003cp\u003e-6.64\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"34.11764705882353%\" valign=\"top\"\u003e\n \u003cp\u003eIsorhamnetin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.11764705882353%\" valign=\"top\"\u003e\n \u003cp\u003e-6.58\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.764705882352942%\" valign=\"top\"\u003e\n \u003cp\u003e-6.79\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"34.11764705882353%\" valign=\"top\"\u003e\n \u003cp\u003eKaempferol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.11764705882353%\" valign=\"top\"\u003e\n \u003cp\u003e-6.25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.764705882352942%\" valign=\"top\"\u003e\n \u003cp\u003e-6.50\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eThe results of molecular docking showed that the binding energies of the two core targets and the three key components were all less than -1.2 kcal/mol, which indicated that they could be spontaneously and stably combined, and that Quercetin, Kaempferol and Isorhamnetin could act on AKT1 and EGFR targets to play an anti-NSCLC role. Among them, the binding energy of EGFR and Isorhamnetin was the lowest (-6.79 kcal/mol) (Fig. 2H, Table 3). From the diagram, it could be found that the main forces between isorhamnetin and EGFR are Carbon Hydrogen Bond, Pi-Sigma, Pi-Sulfur and Pi-Alkyl. Isorhamnetin can form Pi-Alkyl bond with Lysa745, Alaa743 and Vala726 of EGFR, Pi-Sigma bond with Meta790, Leua718 and Leua844, Pi-Sulfur bond with Meta766, and Carbon Hydrogen Bond with meta793, Glna791, Glua792, Lysa745 and Leua718.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCell experiment\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDetermined by cell viability assay\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003eIn this experiment, the effects of Quercetin, Kaempferol and Isorhamnetin on the viability of A549 cells at 6 different concentrations and 3 time points were investigated. The results showed that the viability of A549 cells and the three components showed the dependence between dose and time. The difference between each treatment group and the blank group was statistically significant (P \u0026lt; 0.05), and the inhibitory effect of Isorhamnetin was the strongest. Therefore, the subsequent experiments focused on the effect of Isorhamnetin on A549 cells (Fig. 3A-D). The uncontrolled proliferation of cells is a major feature of tumors. When the tumor proliferates to a certain extent, it will transfer from the original lesion to other parts by means of tumor blood vessels. Therefore, the inhibition of tumor cell proliferation can effectively control tumor progression. It can be seen from the result that the viability of A549 cells was significantly inhibited after treatment with 100 \u0026mu;mol/L Isorhamnetin for 48 h.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCell morphology observation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFrom the inverted microscope and confocal microscope, it could be found that the cell morphology of the blank group was full and irregular paving stone, while the cell morphology of the treatment group became elongated and slender. In the laser confocal microscope image, it could also be observed that the PI dye could not penetrate the membrane due to the integrity of the plasma membrane, , while the Dio dye could penetrate the membrane due to its lipophilicity in the normal group, so the cells in the normal group only have green fluorescence in the cytoplasmic region, while there is no red fluorescence in the nuclear region; however, for the treatment group, due to the influence of isorhamnetin, the cells began to apoptosis and the cell membrane was damaged. Therefore, most cells not only had green fluorescence in the cytoplasmic region, but also had red fluorescence in the nuclear region (Fig. 3E-H). The above results suggest that isorhamnetin will shrink the cytoplasm of A549 cells and recover the pseudopods, thus their morphology will change. At the same time, it will also promote the apoptosis of the cells and lead to the damage of the cell membrane.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCell migration\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe results of scratch test showed that the cell migration rates were 39.30%, 32.40%, 21.02% and 15.17% after 48 h treatment with Isorhamnetin at concentrations of 0, 90, 180 and 270 \u0026mu;mol / L, respectively. Although there was no significant difference between the 90 \u0026mu;mol/L group and the control group, the inhibition of cell migration ability became stronger with the increase of drug concentration. When 180 and 270 \u0026mu;mol/L were compared with the control group, the difference was statistically significant (P \u0026lt; 0.05), indicating that the higher the concentration of Isorhamnetin, the more significant the inhibition of A549 cell migration ability (Fig. 4A-H, M). NSCLC is easy to metastasize, which is closely related to poor prognosis. It can be seen from this experiment that although the low concentration group has no obvious inhibitory effect on the migration of A549 cells, with the increase of administration dose, the viability and migration ability of A549 cells are gradually inhibited. Its migration ability is concentration-dependent, indicating that isorhamnetin can effectively inhibit the migration of A549 cells.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCell invasion\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe results of this experiment showed that with the increase of dosage, the fewer cells penetrated the membrane. The number of A549 cells in the 0, 90, 180 and 270 \u0026mu;mol/L groups was (451 \u0026plusmn; 23.52), (210 \u0026plusmn; 17.52), (119.67 \u0026plusmn; 4.93) and (71.67\u0026plusmn; 13.65), respectively. The difference between the administration group and the control group was statistically significant (P \u0026lt; 0.05) (Fig. 4I-L, N). Therefore, Isorhamnetin can effectively inhibit the invasion of A549 cells, and the higher the concentration, the stronger the inhibitory effect on its invasion ability.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eApoptosis and cell cycle\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe effect of Isorhamnetin on the apoptosis of A549 cells was detected by FITC and PI staining. The results showed that the apoptosis rates of 0,90,180 and 270 \u0026mu;mol/L groups were 7.29%, 15.04%, 23.87% and 30.74 %, respectively. The early apoptosis rate of 90 \u0026mu;mol/L treatment group was 11.94%, while the late apoptosis rate was 3.10%. The early apoptosis rate of 180 \u0026mu;mol/L treatment group was 18.67%, and the late apoptosis rate was 5.20%. The early apoptosis rate of 270 \u0026mu;mol/L treatment group was 20.51%, and the late apoptosis rate was 10.23%. It can be seen that with the increase of drug concentration, the number of apoptotic cells also increased, and the number of late apoptotic cells also increased synchronously. It shows that with the increase of Isorhamnetin concentration, its effect on A549 cells gradually changes from proliferation inhibition to direct killing, and the higher the concentration, the more obvious the effect (Fig. 5A-D). This is also consistent with the results of cell morphology observation, indicating that isorhamnetin can induce apoptosis of A549 cells.\u003c/p\u003e\n\u003cp\u003ePI staining was used to detect the effect of isorhamnetin on the cell cycle of A549 cells. The results showed that the proportion of G1 phase cells in the blank group was 63.17%, while the proportion of G1 phase cells in the 90, 180 and 270 \u0026mu;mol/L groups was 77.73%, 83.49% and 90.92%, respectively. It can be seen that with the increase of drug concentration, the G1 phase arrest is more obvious (Fig. 5E-H). This result further indicated thatA549 cells were arrested in G1 phase, and the process of DNA synthesis and cell division became slower with the increase of drug concentration. It is suggested that isorhamnetin can inhibit DNA replication and promote cell apoptosis, thereby reduce the rate of cell proliferation and controlling tumor diseases.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eWestern blot\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe results of Western blot showed that there was no significant difference in the expression of AKT and PI3K between the blank group and each treatment group (P \u0026gt; 0.05), while the expression of P-AKT and P-PI3K decreased with the increase of drug concentration. Compared with the blank group, there was no statistical significance in the 90 \u0026mu;mol/L group,but there was statistical significance in the 180 and 270 \u0026mu;mol/L groups (P \u0026lt; 0.05) (Fig. 5I-K). From the previous theoretical analysis, it can be seen that the PI3K-Akt signaling pathway has a regulatory effect on a series of biological processes such as proliferation, apoptosis and migration of tumor cells, and the two targets of PI3K and AKT are the core targets of the pathway. It can be seen from the results that the expression of P-PI3K and P-Akt in each treatment group decreased. Although there was no significant difference in the expression between the 90 \u0026mu;mol/L group and the blank group, but the expression decreased with the increase of drug concentration, showing a dose-dependent manner. It was further proved that isorhamnetin can regulate the PI3K-Akt signaling pathway by inhibiting AKT1 and PI3K phosphorylation, thereby inhibit cell growth and proliferation and promoting apoptosis.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eLung cancer is the malignant tumor with the highest mortality rate. As one of the main first-line treatment options, chemotherapy has the disadvantages of poor prognosis and toxic and side effects. Therefore, it is of great significance to explore ways to improve the efficacy and reduce the toxicity of chemotherapy for the treatment of NSCLC. As a traditional disease treatment plan in China, TCM has the characteristics of multi-component, multi-target and multi-channel synergistic treatment of diseases, and has many clinical applications in the treatment of malignant tumors.\u003c/p\u003e \u003cp\u003eIn this study, firstly, three core TCMs for the treatment of NSCLC were screened out by frequency statistics, association rules and cluster analysis. The frequency of these three Chinese medicines in the collected 269 clinical prescriptions was greater than 100, and the HQ reached 175 times, indicating their importance in the treatment of NSCLC. The results of association rule analysis also showed that the frequency of any two simultaneous occurrence of these TCMs was greater than 70, and the frequency of simultaneous occurrence of three TCMs was 52 times. Through cluster analysis, it was found that they were clustered into the same category, indicating that these TCMs have a strong correlation. Among them, HQ has the effects of tonifying qi, consolidating the exterior, diuresis and detoxification. It mainly contains Astragalus polysaccharides, saponins and flavonoids. Zhou et al. ' s research showed that various extracts of HQ had inhibitory effects on breast cancer cells, and can induce apoptosis and regulate PI3K/AKT/mTOR signaling pathway (Zhou et al. \u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e2018\u003c/span\u003e). BZ has the functions of invigorating spleen and replenishing qi, drying dampness and promoting diuresis. The components of BZ include volatile oils, polysaccharides, lactones, vitamins, amino acids, etc. Chen et al. ' s research shows that various components extracted from BZ can induce apoptosis of colorectal cancer cells (Chen et al. \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Poria cocos has the effect of promoting water and dampness, invigorating spleen and calming heart. It contains polysaccharides, triterpenoids, sterols and other components.\u003c/p\u003e \u003cp\u003eIn this study, the anti-NSCLC mechanism of these three TCMs was further analyzed by network pharmacology. Through the PPI network, it can be found that various components of these three TCMs play an anti-NSCLC role through numerous targets, and the core targets EGFR and AKT1 were also screened (Miriam et al. 2024; Chen et al. \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Gao et al. \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Miller et al. 2024). It is reported that the mutation rate of EGFR in Asian NSCLC patients is as high as 50% (Attili et al. \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2020\u003c/span\u003e). The abnormal activation of PI3K-Akt signaling pathway is one of the most common mechanisms of EGFR-TKIs resistance (Wang et al. \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e2016\u003c/span\u003e). However, there is still a lack of effective treatment for EGFR-TKIs resistance mediated by abnormal activation of PI3K-Akt signaling pathway (Tan, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e2020\u003c/span\u003e). AKT1 is an important target in the PI3K-Akt signaling pathway. It is regulated by PI3K and PTEN. Its abnormal activation will promote tumor cell invasion, migration, proliferation and anti-apoptosis. After activation, PI3K accumulates on the cell membrane and phosphorylates 3,4-diphosphate phosphatidylinositol (PIP2) to 3,4,5-triphosphate phosphatidylinositol (PIP3) (Tiwari et al. \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e2017\u003c/span\u003e). PIP3 binds to AKT and activates Thr308 and Ser473 sites. The activated AKT then activates the mTOR signaling pathway, regulates protein synthesis and cell growth, promotes cell proliferation, and inhibits apoptosis. PTEN is the first known tumor suppressor gene with phosphatase activity. It antagonizes PI3K and inhibits AKT activation by promoting dephosphorylation of PIP3 at D3 to generate PIP2(Li et al. \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e2016\u003c/span\u003e). The results of KEGG enrichment analysis showed that EGFR tyrosine kinase inhibitor resistance and PI3K-Akt signaling pathway, which are closely related to EGFR and AKT1, were significantly enriched. It also proved that there was a strong correlation between the three traditional Chinese medicines screened in the previous study and the enriched targets and pathways. They may form a network of mutual synergy and interaction through these targets and pathways, thus playing a therapeutic role in NSCLC. The results of GO enrichment analysis also prove this point.\u003c/p\u003e \u003cp\u003eThe experimental results of CCK-8 showed that the three core components of quercetin, kaempferol and isorhamnetin screened in this study all had anti-NSCLC activity in a concentration-dependent and time-dependent manner, and isorhamnetin had the best inhibitory effect. Combined with scratch test and transwell test, it can be seen that isorhamnetin not only inhibits the proliferation, but also inhibits migrate and invade ability of A549 cells. It can be seen from the flow cytometry results that isorhamnetin inhibits the proliferation of A549 cells in two aspects: on the one hand, it promotes apoptosis, and on the other hand, it mediates cell cycle arrest. The rapid proliferation and metastasis of tumor cells are closely related to the disease progression of patients. If the proliferation and metastasis of tumor cells are inhibited, the speed and risk of deterioration of patients can be reduced. In order to verify whether isorhamnetin acts on A549 cells through the PI3K-Akt signaling pathway, this study performed Western blot experiments on PI3K and AKT, two key targets of the PI3K-Akt signaling pathway. PI3K has three expression types, among which PI3KI is most associated with the occurrence and development of cancer (Fruman et al. \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e2017\u003c/span\u003e). It can phosphorylate PIP2 to PIP3, and then transfer Akt to the plasma membrane to activate it. Akt contains three homologous genes: Akt1, Akt2 and Akt3.After activation, it will further activate its downstream target proteins to mediate the growth, invasion, metastasis and anti-apoptosis of tumor cells (Revathidevi et al. \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e2019\u003c/span\u003e). From the experimental results, it can be seen that the P-AKT/AKT and P-PI3K/PI3K in the treatment group were significantly lower than those in the control group, indicating that the AKT phosphorylation process was inhibited by isorhamnetin, indicating that the PI3K-Akt signaling pathway is one of the mechanisms by which isorhamnetin inhibits A549 cells.\u003c/p\u003e \u003cp\u003eFrom the results of KEGG and GO enrichment analysis, it can be seen that the inhibitory mechanism of the core traditional Chinese medicine screened in this study on NSCLC is not only related to the PI3K-Akt signaling pathway, but also the active components of these three traditional Chinese medicines against NSCLC are not only quercetin, kaempferol and isorhamnetin. In the existing reports, they also have many components with anti-tumor activity (Yang et al. \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e2024\u003c/span\u003e; Zhang et al. \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Qiao et al. \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Xie et al. \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e2024\u003c/span\u003e). Therefore, further research on these anti-tumor active drugs is needed to screen out more anti-tumor active components for new drug development and clinical application.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIn this study, the medication rules of 269 prescriptions for the treatment of NSCLC were analyzed. The results showed that the frequency of HQ, BZ and FL was higher than 100, and the association rule analysis also showed that they were highly correlated and clustered into the same category in cluster analysis, indicating that they had potential synergistic effects in the treatment of NSCLC and might be the core Chinese medicine for the treatment of NSCLC. In this study, 116 potential targets of these three core TCMs for NSCLC were collected. Through PPI network construction and mapping relationship between components and targets, we found out three key components of these three TCMs, quercetin, kaempferol and isorhamnetin, as well as the core targets AKT1 and EGFR for the treatment of NSCLC. Molecular docking verified that they could be stably combined; at the same time, through enrichment analysis, it was found that the mechanism of these three Chinese medicines in the treatment of NSCLC may be related to the PI3K-Akt pathway. Subsequent cell experiments further proved that Quercetin, Kaempferol and Isorhamnetin all had the effect of inhibiting A549 cells, and Isorhamnetin had the best effect. Isorhamnetin also inhibited the proliferation, migration and invasion of A549 cells, induced apoptosis and cell cycle arrest, and inhibited the phosphorylation of AKT1 and PI3K.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAuthor contributions\u0026nbsp;\u003c/strong\u003eQian Tang \u0026amp; Xuefang Zheng：Conceptualization, Funding acquisition, Project administration, Writing-review \u0026amp; editing.\u003c/p\u003e\n\u003cp\u003eYu Tang：Methodology, Investigation, Writing-original draft, Preparation, Writing-review \u0026amp; editing.\u003c/p\u003e\n\u003cp\u003eZhengping Xian：Investigation, Preparation, Technical supports, Writing-review \u0026amp; editing.\u003c/p\u003e\n\u003cp\u003eFengjiao Wu：Technical supports.\u003c/p\u003e\n\u003cp\u003eHongyu Cao：Software, Writing-review \u0026amp; editing.\u003c/p\u003e\n\u003cp\u003eLihao Wang：Writing-review \u0026amp; editing.\u003c/p\u003e\n\u003cp\u003eYanan Du：Writing-review \u0026amp; editing.\u003c/p\u003e\n\u003cp\u003eThe authors declare that all data were generated in-house and that no paper mill was used.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e This work was financially supported by the National Natural Science Foundation of China (NO. 21571025，No.21601024，No.21601025), the subject construction project-the interdisciplinary project of Dalian University (DLUXK-2023-YB-007).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability\u0026nbsp;\u003c/strong\u003eThe data that support the findings of this study are available from the corresponding author upon reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e The authors declare no competing interests.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthical approval\u0026nbsp;\u003c/strong\u003eNot applicable.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eAcharya B et al (2022) \u0026beta;-Eudesmol Inhibits the Migration of Cholangiocarcinoma Cells by Suppressing Epithelial-Mesenchymal Transition via PI3K/AKT and p38MAPK Modulation. Asian Pac J Cancer Prev 23(8):2573-2581\u003c/li\u003e\n\u003cli\u003eAttili I et al (2020) Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way. Ann Transl Med 8(17): 1111\u003c/li\u003e\n\u003cli\u003eBray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229-263\u003c/li\u003e\n\u003cli\u003eChen H et al (2023) Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations. J Med Chem 66(17): 11656-11671\u003c/li\u003e\n\u003cli\u003eChen LX et al (2024) Yi Qi Chu Tan Formula (YQCTF) inhibited the progress of lung cancer via regulating tumor-associated neutrophil: An integrated study of network pharmacology, proteomics and pharmacodynamics. J Ethnopharmacol 318(Pt B): 116943\u003c/li\u003e\n\u003cli\u003eChen TQ et al (2023) Six polyacetylenes from Atractylodes macrocephala Koidz and their anti-colon cancer activity. Fitoterapia 167, 105490\u003c/li\u003e\n\u003cli\u003eChen XM et al (2019) Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-\u0026gamma;. Front Pharmacol 10, 898\u003c/li\u003e\n\u003cli\u003eDou SH et al (2021) Atractylenolide II induces cell cycle arrest and apoptosis in breast cancer cells through ER pathway. Pak J Pharm Sci 34(4):1449\u0026ndash;1458\u003c/li\u003e\n\u003cli\u003eFei MH et al (2023) Effects of Modified Baizhu Shaoyao San on Postoperative Diarrhea in Colorectal Cancer Patients: A Single-Blind, Randomized Controlled Trial. Complement Med Res 30(1):37\u0026ndash;44\u003c/li\u003e\n\u003cli\u003eFruman D. A et al (2017). The PI3K Pathway in Human Disease. Cell 170(4):605\u0026ndash;635\u003c/li\u003e\n\u003cli\u003eGao HL et al (2023) The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells. Front Pharmacol 14:1235285\u003c/li\u003e\n\u003cli\u003eGaron E. B et al (2019). Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol 37(28):2518\u0026ndash;2527\u003c/li\u003e\n\u003cli\u003eHe Y et al (2021) Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6(1):425\u003c/li\u003e\n\u003cli\u003eHe ZQ et al (2024) Anticancer Mechanism of \u003cem\u003eAstragalus\u003c/em\u003e Polysaccharide and Its Application in Cancer Immunotherapy. Pharmaceuticals (Basel) 17:5 636\u003c/li\u003e\n\u003cli\u003eJiang F et al (2023) Pachymic Acid Inhibits Growth and Metastatic Potential in Liver Cancer HepG2 and Huh7 Cells. Biol Pharm Bull 46(1):35\u0026ndash;41\u003c/li\u003e\n\u003cli\u003eJim\u0026eacute;nez J et al (2017) DeepSite: protein-binding site predictor using 3D-convolutional neural networks. Bioinformatics 33(19):3036\u0026ndash;3042\u003c/li\u003e\n\u003cli\u003eKhezri M. R et al (2022) The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions. Exp Mol Pathol 127: 104787\u003c/li\u003e\n\u003cli\u003eLi SJ. J et al (2016) Wogonin induces Beclin-1/PI3K and reactive oxygen species-mediated autophagy in human pancreatic cancer cells. Oncol Lett 12(6):5059\u0026ndash;5067\u003c/li\u003e\n\u003cli\u003eLong XM et al (2023) Network-based Pharmacology and \u003cem\u003eIn vitro\u003c/em\u003e Validation Reveal that Galangin Induces Apoptosis in Bladder Cancer Cells by Promoting the P53 Signaling Pathway. Anticancer Agents Med Chem 23(7):847\u0026ndash;857\u003c/li\u003e\n\u003cli\u003eMao JJ et al (2022) Effects of Atractylon on Proliferation and Apoptosis of Intestinal Cancer Cells Through PI3K/AKT/mTOR Signaling Pathway. Cell Mol Biol (Noisy-le-grand) 68(5):153\u0026ndash;160\u003c/li\u003e\n\u003cli\u003eMiriam Dorta-Su\u0026aacute;rez et al (2024) The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives. Cancer Treat Rev 124: 102671\u003c/li\u003e\n\u003cli\u003eMiller Karina A et al (2024) PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression. Oncogene 43(1):22-34\u003c/li\u003e\n\u003cli\u003ePeng L et al (2020) Anti-cancer activity of Conyza blinii saponin against cervical carcinoma through MAPK/TGF-\u0026beta;/Nrf2 signaling pathways. J Ethnopharmacol 251:112503\u003c/li\u003e\n\u003cli\u003eQiao PF et al (2023) Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer \u003cem\u003evia\u003c/em\u003e targeting Hsp27. Front Oncol 6(12):1084884\u003c/li\u003e\n\u003cli\u003eRevathidevi S et al (2019) Akt in cancer: Mediator and more. Semin Cancer Biol 59:80\u0026ndash;91\u003c/li\u003e\n\u003cli\u003eSt Claire S et al (2020) Lung health, tobacco, and related products: gaps, challenges, new threats, and suggested research. American journal of physiology. Am J Physiol Lung Cell Mol Physiol 318(5): L1004\u0026ndash;L1007\u003c/li\u003e\n\u003cli\u003eTan A. C (2020) Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer 11(3):511\u0026ndash;518\u003c/li\u003e\n\u003cli\u003eTiwari V et al (2017) Akt1/NF\u0026kappa;B signaling pathway activation by a small molecule DMA confers radioprotection to intestinal epithelium in xenograft model. Free Radic Biol Med 108:564\u0026ndash;574\u003c/li\u003e\n\u003cli\u003eWang J et al (2016) Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther 9:3711\u0026ndash;3726\u003c/li\u003e\n\u003cli\u003eWang YS et al (2020) Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomed Pharmacother 121:109570\u003c/li\u003e\n\u003cli\u003eWei JR et al (2024) Lianhua Qingwen exerts anti-liver cancer effects and synergistic efficacy with sorafenib through PI3K/AKT pathway: Integrating network pharmacology, molecular docking, and experimental validation. Gene 912:148383\u003c/li\u003e\n\u003cli\u003eXiao ZW et al (2021) Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer: A randomized, controlled trial. Medicine (Baltimore) 100 (18): e25690\u003c/li\u003e\n\u003cli\u003eXie ZN et al (2024) Insights into the inhibition of stomach cancer MKN45 cell growth by Poria cocos ethanol-soluble extract based on MAPK/PI3K signaling pathways and components cell fishing. J Ethnopharmacol 10 (320):117417\u003c/li\u003e\n\u003cli\u003eXu F et al (2018) Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling. J Exp Clin Cancer Res 37(1):207\u003c/li\u003e\n\u003cli\u003eXu HC et al (2021) Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. J Clin Invest 131(10):e146832\u003c/li\u003e\n\u003cli\u003eYang Q et al (2024) Advances in research on the anti-tumor mechanism of \u003cem\u003eAstragalus\u003c/em\u003e polysaccharides. Front Oncol 14:1334915\u003c/li\u003e\n\u003cli\u003eYang RY et al (2024) Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis. Phytomedicine 122: 155135\u003c/li\u003e\n\u003cli\u003eYin YF et al (2022) Icariin Regulates the hsa_circ_0003159/eIF4A3/bcl-2 Axis to Promote Gastric Cancer Cell Apoptosis. Evid Based Complement Alternat Med 2022:1955101\u003c/li\u003e\n\u003cli\u003eYu L et al (2022) Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol 85:69\u0026ndash;94\u003c/li\u003e\n\u003cli\u003eZhang D et al (2022) Atractylenolide III induces apoptosis by regulating the Bax/Bcl-2 signaling pathway in human colorectal cancer HCT-116 Cells in vitro and in vivo. Anticancer Drugs 33(1):30\u0026ndash;47\u003c/li\u003e\n\u003cli\u003eZhang LJ et al (2023) Astragaloside II enhanced sensitivity of ovarian cancer cells to cisplatin via triggering apoptosis and autophagy. Cell Biol Int 47(9):1600-1613\u003c/li\u003e\n\u003cli\u003eZhang XY et al (2022) Clinical study on Yanghe decoction in improving neo-adjuvant chemotherapy efficacy and immune function of breast cancer patients. Medicine (Baltimore) 101(10):e29031\u003c/li\u003e\n\u003cli\u003eZhang YM et al (2019) The Effects of Astragalus Polysaccharide on Bone Marrow-Derived Mesenchymal Stem Cell Proliferation and Morphology Induced by A549 Lung Cancer Cells. Med Sci Monit 25:4110\u0026ndash;4121\u003c/li\u003e\n\u003cli\u003eZhang ZP et al (2024) Modified Banxiaxiexin decoction benefitted chemotherapy in treating gastric cancer by regulating multiple targets and pathways. J Ethnopharmacol 331: 118277\u003c/li\u003e\n\u003cli\u003eZhao WJ et al (2024) Si Jun Zi decoction inhibits the growth of lung cancer by reducing the expression of PD-L1 through TLR4/MyD88/NF-\u0026kappa;B pathway. J Ethnopharmacol 318(Pt A):116948\u003c/li\u003e\n\u003cli\u003eZheng RS et al (2022) Cancer incidence and mortality in China, 2016. JNCC 2 (1):1-9.\u003c/li\u003e\n\u003cli\u003eZhou RJ et al (2018) Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway. BMC Complement Altern Med 18(1):83\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"naunyn-schmiedebergs-archives-of-pharmacology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"nsap","sideBox":"Learn more about [Naunyn-Schmiedeberg's Archives of Pharmacology](https://www.springer.com/journal/210)","snPcode":"210","submissionUrl":"https://submission.nature.com/new-submission/210/3","title":"Naunyn-Schmiedeberg's Archives of Pharmacology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Non-small cell lung cancer, Traditional Chinese medicine, Medication rules, Network pharmacology, Molecular docking, Experimental validation","lastPublishedDoi":"10.21203/rs.3.rs-4648678/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4648678/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eIn the course of clinical treatment for anti-tumor, the combination of traditional Chinese medicine (TCM) and other treatment schemes can reduce toxicity and increase efficiency. The purpose of this paper is to find out the key TCM and effective components for the treatment of non-small cell lung cancer (NSCLC) and analyze its therapeutic mechanism by analyzing the prescription of TCM combined with chemotherapy for NSCLC. Firstly, the prescriptions of TCM in the randomized controlled trials combined with chemotherapy for NSCLC were collected, and the core TCM was screened by frequency statistics, association rule analysis and cluster analysis. Then, the intersection targets of the potential effects of NSCLC and core Chinese medicine were collected, and PPI analysis and enrichment analysis were performed on the intersection targets to screen the core targets, components and pathways, and the core components were verified by molecular docking and cell experiments. In this study, 269 prescriptions were collected, among which the frequency of medication for Astragalus membranaceus (HQ, in Chinese), Wolfiporia cocos (FL, in Chinese), Atractylodes macrocephala (BZ, in Chinese) was over 100. Association rule analysis showed that they were highly correlated and clustered into the same category in cluster analysis. Their core components were Quercetin, Kaempferol and Isorhamnetin. The molecular docking results of the core components with the core targets AKT1 and EGFR obtained by PPI network analysis showed that they could bind stably. KEGG analysis screened 110 pathways including PI3K-Akt; the results of CCK-8 showed that Quercetin, Kaempferol and Isorhamnetin could effectively inhibit the proliferation of A549 cells, and Isorhamnetin had the best inhibitory effect. Isorhamnetin can inhibit the migration and invasion of A549 cells, induce apoptosis, G1 phase arrest, and decrease the expression of P-PI3K and P-AKT in A549 cells. In a word, the key TCM for the treatment of NSCLC include HQ, FL, BZ, etc. and its key components Quercetin, Kaempferol, Isorhamnetin have potential therapeutic effects on NSCLC according to the research results.\u003c/p\u003e","manuscriptTitle":"Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: Key drug screening and mechanism analysis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-07-19 15:43:12","doi":"10.21203/rs.3.rs-4648678/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-07-13T01:03:27+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-07-12T00:37:34+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-07-07T12:49:12+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"205957571649104945244768726430977583089","date":"2024-07-05T05:59:02+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"115288196719445358028665501004083944908","date":"2024-07-03T12:18:14+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"126272392991175521883707972526599552752","date":"2024-07-01T00:16:56+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-06-30T20:46:54+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-06-28T04:37:09+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-06-28T04:35:41+00:00","index":"","fulltext":""},{"type":"submitted","content":"Naunyn-Schmiedeberg's Archives of Pharmacology","date":"2024-06-27T12:54:46+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"naunyn-schmiedebergs-archives-of-pharmacology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"nsap","sideBox":"Learn more about [Naunyn-Schmiedeberg's Archives of Pharmacology](https://www.springer.com/journal/210)","snPcode":"210","submissionUrl":"https://submission.nature.com/new-submission/210/3","title":"Naunyn-Schmiedeberg's Archives of Pharmacology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"018bcbdf-4b20-459e-8798-58c16d71ab14","owner":[],"postedDate":"July 19th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2024-08-05T16:03:10+00:00","versionOfRecord":{"articleIdentity":"rs-4648678","link":"https://doi.org/10.1007/s00210-024-03310-5","journal":{"identity":"naunyn-schmiedebergs-archives-of-pharmacology","isVorOnly":false,"title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},"publishedOn":"2024-07-29 15:57:35","publishedOnDateReadable":"July 29th, 2024"},"versionCreatedAt":"2024-07-19 15:43:12","video":"","vorDoi":"10.1007/s00210-024-03310-5","vorDoiUrl":"https://doi.org/10.1007/s00210-024-03310-5","workflowStages":[]},"version":"v1","identity":"rs-4648678","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4648678","identity":"rs-4648678","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}